Guggenheim Maintains Buy on Jade Biosciences, Raises Price Target to $32

Jade Biosciences, Inc.

Jade Biosciences, Inc.

JBIO

0.00

Guggenheim analyst Vamil Divan maintains Jade Biosciences (NASDAQ: JBIO) with a Buy and raises the price target from $23 to $32.